Remote proctoring in complex percutaneous coronary intervention aided by mixed reality technology.
Coronary intervention
HoloLens 2
Mixed reality
Remote proctoring
Journal
European heart journal. Digital health
ISSN: 2634-3916
Titre abrégé: Eur Heart J Digit Health
Pays: England
ID NLM: 101778323
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
received:
12
02
2024
revised:
14
03
2024
accepted:
26
03
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
epublish
Résumé
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) has a lower success rate and a higher complication rate compared to PCI of non-occluded coronary arteries. Co-operation and supervision by a more experienced operator (proctoring) are associated with improved success of CTO procedures. This study aims to assess the feasibility of remote proctoring using web-based communication and mixed reality technology in CTO procedures. The PCI operator was equipped with a Microsoft HoloLens 2 head-mounted display enabling visual and verbal interaction including holographic annotations with a remote proctor. Ten CTO procedures were performed by a single PCI operator assisted by a remote proctor. Audio and video communication was successfully established in all procedures. All procedures were possible to perform with a Microsoft HoloLens 2 head-mounted display. The PCI operator experienced the remote proctoring as useful. Remote proctoring of CTO procedures using mixed reality technology was feasible. The impact of the method regarding procedural and patient outcomes needs to be assessed in new studies.
Identifiants
pubmed: 39318687
doi: 10.1093/ehjdh/ztae037
pii: ztae037
pmc: PMC11417479
doi:
Types de publication
Journal Article
Langues
eng
Pagination
633-636Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: S.C., J.O.A., and C.H.E. report no disclosures. J.J. reports lecture fees from Pfizer, BMS, Boehringer Ingelheim, and Sanofi and advisory board fees from Amarin and AstraZeneca.